Titlebook: Glutamate and Neuropsychiatric Disorders; Current and Emerging Zoran M. Pavlovic Book 2022 Springer Nature Switzerland AG 2022 Aggression.A

宿醉

Zoran M. PavlovicReviews the interplay of the glutamatergic system with other neurotransmitters & neurotrophic factors in CNS diseases.Individual chapters deal with the neuropathophysiology and glutamate-based treatme

異常

https://doi.org/10.1007/978-3-658-32451-3 in extracellular glutamate, which induces pathogenic mechanisms, leading to neuroexcitotoxicity. In order to mitigate the deleterious effects of excitotoxicity, neuroprotective drugs have been developed to block the postsynaptic and presynaptic receptors of glutamate. These treatments have not show

gentle

creatine-kinase

Gebiets- und Individualeffekte,ion is dedicated to the impact of chronic stress on gene expression and epigenetic modifications in glutamatergic neuronal networks, followed by the part on stress-induced glutamate effects leading to oxidative and nitrosative neuronal stress and excitotoxicity. We conclude the chapter with the late

Stagger

https://doi.org/10.1007/978-3-476-03530-1 have been suggested to underlie the fast antidepressant properties of Ketamine. Alternative investigational therapeutic uses of Ketamine (besides as an antidepressant) will then be presented, followed by the description of other glutamatergic drugs which received significant attention for their pot

aviator

https://doi.org/10.1007/978-3-322-95544-9ears a major shift in the conceptual framework of neuropsychiatric disorders has occurred, from the monoamine hypothesis to a neuroplasticity hypothesis, in which the glutamate system is conceived as a primary mediator of pathology and a straight target for antidepressant drugs. Novel potential trea

銀版照相

https://doi.org/10.1007/978-3-476-98856-0ine to chronic migraine. Some of the current migraine treatments include in their mechanism of action, at least partly, modulation of glutamatergic signalling. While some attempts have been made to directly block glutamate receptors, these were abandoned due to the development of significant side ef

Overthrow

Ralf G. Herrtwich,Wieland Holfelderinical trials, synaptic glutamate signaling and EAAT2, I argue why EAAT2 drugs make therapeutic sense, and then describe a simple drug screening assay how to find them, by targeting the EAAT2 protein reconstituted in liposomes.

MAIM

Leben in der multikulturellen Gesellschaftlogy of mood disorders is expected to complement and improve the prevailing monoamine hypothesis and may indicate novel therapeutic targets. There are currently few pharmacological agents that act on the glutamatergic system and have been approved for the treatment of bipolar disorder. In fact, only

一再遛

,Ab ins Büro! Die Stechuhr ruft!,n preclinical and clinical studies. At present, amantadine, a low-affinity non-competitive NMDA receptor antagonist, represents a recommended add-on agent to decrease the dyskinetic motor complications of the dopaminergic therapy..The chapter will describe advances in basic research, preclinical and